2023 World Conference on Lung Cancer (Posters)-P1.21. Eosinophil to Neutrophil Ratio Predicts Efficacy in Patients Receiving Immunotherapy in Metastatic Non-small Cell Lung Cancer (mNSCLC)

P1.21. Eosinophil to Neutrophil Ratio Predicts Efficacy in Patients Receiving Immunotherapy in Metastatic Non-small Cell Lung Cancer (mNSCLC) - PDF(Slides)

Back to course

Pdf Summary

A study conducted at Westmead and Blacktown hospitals examined the impact of eosinophil-to-neutrophil ratios (ENR) on the efficacy of immunotherapy (IO) in patients with metastatic non-small cell lung cancer (mNSCLC). Eosinophilia, an increase in eosinophils, has been observed in patients receiving IO and is associated with a good prognosis. In contrast, a high neutrophil-to-lymphocyte ratio (NLR) is predictive of a poor outcome in NSCLC.<br /><br />The researchers collected clinical data from patients who received IO monotherapy between 2018 and 2022. They found that a high peak ENR, but not baseline ENR or NLR, was associated with a higher objective response rate (ORR), as well as improved overall survival (OS) after 9 weeks of IO treatment. This association remained significant even after adjusting for other known risk factors.<br /><br />The study highlights the potential of using ENR as a predictive marker in patients with mNSCLC receiving IO. High ENR was associated with better response to treatment and improved survival outcomes. The findings suggest that ENR could be used as a biomarker to identify patients who are likely to benefit from IO.<br /><br />The researchers also emphasize the need for further basic science research into the role of eosinophils in anti-tumor immunity. This knowledge could help in the development of novel therapies that target eosinophils and enhance the efficacy of IO.<br /><br />In conclusion, this study demonstrates that ENR is a promising predictive marker for the efficacy of IO in patients with mNSCLC. High ENR is associated with better treatment response and improved survival outcomes. Further research is warranted to better understand the role of eosinophils in anti-tumor immunity and to explore the potential use of ENR as a biomarker in clinical practice.

Asset Subtitle

Joe Wei

Meta Tag

Speaker Joe Wei

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

eosinophil-to-neutrophil ratios

immunotherapy

metastatic non-small cell lung cancer

eosinophilia

neutrophil-to-lymphocyte ratio

clinical data

objective response rate

overall survival

predictive marker

anti-tumor immunity